glp-1 drugs covered by insurance Costs Explained: Managing Coverage Challenges Employers Take a Variety of

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al

Supply Chain Disruptions: The availability of these critical medications is affected by manufacturing challenges and supply chain issues

As with treatment for hypertension or diabetes, chronic conditions require ongoing therapy

At present, the available evidence suggests that both GLP-1 agonist and SGLT2 inhibitors produce unfavourable outcomes, and should be avoided in pregnancy and during lactation

Also, Australia, the USA and the UK differ in the GLP-1RAs that have received regulatory approval

however, those who persisted with the medication coverage experienced weight losses comparable with those shown in corresponding clinical trials. And in a paper published in 2023, researchers found that while significant weight loss was achievable with GLP-1s among type 2 diabetes patients, the average weight reduction was relatively modest, 2.2% after 72 weeks of being on the medications